News

A new report has found mortality rates for 5 of the 12 leading causes of death in the United States have increased since 2000.
A national survey demonstrated gaps in medical providers’ knowledge about changes to HIV health care delivery due to the Affordable Care Act.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label.
Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.
The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.

Product News

Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
Repatha (evolocumab) treats primary hyperlipidemia in combination with dietary measures and maximally tolerated doses of statins.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$